Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran Etexilate HPMC vs Gelatine Capsule
NCT02170597Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2003
- Primary completion
- Sep 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in thromboembolism (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma concentration time curve from zero time extrapolated to infinity, Area under the plasma concentration time curve from zero time to the time of the last quantifiable concentration and 2 more. Started Aug 2003; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02170597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170597.